Matteucci Elena, Cupisti Adamasco, Caprioli Raffaele, Battipaglia Elena, Favilla Stefania, Rindi Paolo, Barsotti Giuliano, Giampietro Ottavio
Department of Internal Medicine, University of Pisa, Via Rome 67, 56126 Pisa, Italy.
Nutr Metab Cardiovasc Dis. 2007 May;17(4):288-93. doi: 10.1016/j.numecd.2005.11.011. Epub 2006 Mar 20.
Patients with chronic renal failure, especially those treated with haemodialysis, have an increased risk of developing atherosclerotic vascular disease probably as a result of enhanced oxidative stress. The human cell membrane possesses electron transfer systems which protect against extracellular pro-oxidant challenge. We evaluated (1) the erythrocyte velocity of ferricyanide reduction (RBC vfcy) in 25 uraemic patients (aged 25-71 years; 14 males), (2) the changes induced by a single haemodialysis session and (3) biomarkers of oxidative stress.
Before and after a mid-week dialysis session, we measured RBC vfcy, erythrocyte glutathione (RBC GSH), plasma and red cell membrane malondialdehyde (P and RBC MDA), plasma sulphydryl groups (P SH), plasma vitamin C levels and haemolysis percentage. Pre-dialysis RBC GSH (0.68+/-0.13 vs 0.80+/-0.13 mg/mL, p<0.01), P SH (266+/-74 vs 406+/-78 micromol/L, p<0.01) and plasma vitamin C (7.0+/-5.1 vs 21.5+/-8.5mg/L, p<0.001) were lower than in 25 age-sex-matched healthy controls; P MDA (1.57+/-0.52 vs 0.54+/-0.29 nmol/mL, p<0.001), RBC MDA (0.42+/-0.13 vs 0.34+/-0.16 nmol/mL, p<0.05) and haemolysis (1.2+/-0.3 vs 0.7+/-0.3%, p<0.001) were increased. Baseline RBC vfcy did not differ from normals (13.1+/-5.2 vs 12.9+/-3.2 mmol/mL/h). Following dialysis, RBC vfcy (to 8.9+/-4.5 mmol/mL/h, p<0.001) decreased, as well as P MDA, RBC MDA and plasma vitamin C (to 2.5+/-1.4 mg/L, p<0.001), whereas P SH groups increased (to 413+/-99 micromol/L, p<0.001); haemolysis percentage remained high. RBC vfcy values were correlated to RBC GSH and vitamin C levels.
Uraemic patients showed signs of oxidative stress. Pre-dialysis RBC vfcy is maintained in the normal range on account of a reduced intracellular content of GSH and in spite of low plasma ascorbate. A single haemodialysis treatment reduced biomarkers of protein and lipid oxidation but markedly impaired transmembrane electron transfer, which could be explained by acute depletion of electron donors.
慢性肾衰竭患者,尤其是接受血液透析治疗的患者,发生动脉粥样硬化性血管疾病的风险增加,这可能是氧化应激增强所致。人体细胞膜拥有电子传递系统,可抵御细胞外促氧化剂的攻击。我们评估了(1)25例尿毒症患者(年龄25 - 71岁;14例男性)的红细胞铁氰化物还原速度(RBC vfcy),(2)单次血液透析治疗所引起的变化,以及(3)氧化应激生物标志物。
在一周中进行透析治疗前后,我们测量了RBC vfcy、红细胞谷胱甘肽(RBC GSH)、血浆和红细胞膜丙二醛(P和RBC MDA)、血浆巯基(P SH)、血浆维生素C水平及溶血百分比。透析前,RBC GSH(0.68±0.13对0.80±0.13mg/mL,p<0.01)、P SH(266±74对406±78μmol/L,p<0.01)和血浆维生素C(7.0±5.1对21.5±8.5mg/L,p<0.001)低于25例年龄和性别匹配的健康对照者;P MDA(1.57±0.52对0.54±0.29nmol/mL,p<0.001)、RBC MDA(0.42±0.13对0.34±0.16nmol/mL,p<0.05)和溶血(1.2±0.3对0.7±0.3%,p<0.001)增加。基线RBC vfcy与正常对照无差异(13.1±5.2对12.9±3.2mmol/mL/h)。透析后,RBC vfcy(降至8.9±4.5mmol/mL/h,p<0.001)降低,P MDA、RBC MDA和血浆维生素C也降低(降至2.5±1.4mg/L,p<0.001),而P SH组增加(至413±99μmol/L,p<0.001);溶血百分比仍较高。RBC vfcy值与RBC GSH和维生素C水平相关。
尿毒症患者表现出氧化应激迹象。透析前RBC vfcy维持在正常范围内,这是由于细胞内GSH含量降低,尽管血浆抗坏血酸水平较低。单次血液透析治疗降低了蛋白质和脂质氧化的生物标志物,但显著损害了跨膜电子传递能力,这可能是由于电子供体的急性耗竭所致。